PMC:6707402 / 15315-16293
Annnotations
MyTest
{"project":"MyTest","denotations":[{"id":"31489176-20426544-30448250","span":{"begin":226,"end":228},"obj":"20426544"},{"id":"31489176-8101399-30448251","span":{"begin":230,"end":232},"obj":"8101399"},{"id":"31489176-18422859-30448252","span":{"begin":234,"end":236},"obj":"18422859"},{"id":"31489176-18422859-30448253","span":{"begin":261,"end":263},"obj":"18422859"},{"id":"31489176-20426544-30448254","span":{"begin":269,"end":271},"obj":"20426544"},{"id":"31489176-11346704-30448255","span":{"begin":294,"end":296},"obj":"11346704"},{"id":"31489176-8101399-30448256","span":{"begin":298,"end":300},"obj":"8101399"},{"id":"31489176-18422859-30448257","span":{"begin":302,"end":304},"obj":"18422859"},{"id":"31489176-11346704-30448258","span":{"begin":330,"end":332},"obj":"11346704"},{"id":"31489176-18422859-30448259","span":{"begin":338,"end":340},"obj":"18422859"},{"id":"31489176-8101399-30448260","span":{"begin":380,"end":382},"obj":"8101399"},{"id":"31489176-10918419-30448261","span":{"begin":425,"end":427},"obj":"10918419"},{"id":"31489176-8101399-30448262","span":{"begin":462,"end":464},"obj":"8101399"},{"id":"31489176-28301051-30448263","span":{"begin":512,"end":514},"obj":"28301051"},{"id":"31489176-11346704-30448264","span":{"begin":565,"end":567},"obj":"11346704"},{"id":"31489176-18422859-30448265","span":{"begin":569,"end":571},"obj":"18422859"},{"id":"31489176-28301051-30448266","span":{"begin":573,"end":575},"obj":"28301051"},{"id":"31489176-18422859-30448267","span":{"begin":600,"end":602},"obj":"18422859"},{"id":"31489176-28301051-30448268","span":{"begin":608,"end":610},"obj":"28301051"},{"id":"31489176-11346704-30448269","span":{"begin":638,"end":640},"obj":"11346704"},{"id":"31489176-18422859-30448270","span":{"begin":642,"end":644},"obj":"18422859"},{"id":"31489176-18422859-30448271","span":{"begin":667,"end":669},"obj":"18422859"},{"id":"31489176-11346704-30448272","span":{"begin":675,"end":677},"obj":"11346704"},{"id":"31489176-28301051-30448273","span":{"begin":707,"end":709},"obj":"28301051"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Table 4. Cardiovascular and respiratory adverse reactions observed per number of treatments.\nAdverse reaction Studies Total number of treatments Adverse reactions observed, n (%) (min%–max%) †\nCardiac\n Hypotension ‡ [ 40, 51, 68] 323 10 (3) (2–14) [ 68] - [ 40]\n Hypertension ‡ [ 25, 51, 68] 425 60 (14) (3–21) [ 25] - [ 68]\n Bradycardia (mild and severe) ‡ [ 51] 54 4 (7)\n Decrease in heartrate ‡ [ 39] 32 30 (94)\n Tachycardia ‡ [ 51] 54 4 (7)\n Cardiac event, unspecified ‡ [ 74] 1269 35 (3)\n Chest discomfort/tightness ‡ [ 25, 68, 74] 1640 83 (5) (0–6) [ 68] - [ 74]\nRespiratory\n Dyspnea [ 25, 68] 371 3 (1) (0–2) [ 68] - [ 25]\n Shortness of breath ‡ [ 74] 1269 40 (3)\n†Incidences of the adverse reactions have been calculated for all the individual studies. (%, min-max) are the lowest and highest observed incidence of an adverse reaction observed in the group of studies included.\n‡ DMSO was administered intravenously."}
2_test
{"project":"2_test","denotations":[{"id":"31489176-20426544-30448250","span":{"begin":226,"end":228},"obj":"20426544"},{"id":"31489176-8101399-30448251","span":{"begin":230,"end":232},"obj":"8101399"},{"id":"31489176-18422859-30448252","span":{"begin":234,"end":236},"obj":"18422859"},{"id":"31489176-18422859-30448253","span":{"begin":261,"end":263},"obj":"18422859"},{"id":"31489176-20426544-30448254","span":{"begin":269,"end":271},"obj":"20426544"},{"id":"31489176-11346704-30448255","span":{"begin":294,"end":296},"obj":"11346704"},{"id":"31489176-8101399-30448256","span":{"begin":298,"end":300},"obj":"8101399"},{"id":"31489176-18422859-30448257","span":{"begin":302,"end":304},"obj":"18422859"},{"id":"31489176-11346704-30448258","span":{"begin":330,"end":332},"obj":"11346704"},{"id":"31489176-18422859-30448259","span":{"begin":338,"end":340},"obj":"18422859"},{"id":"31489176-8101399-30448260","span":{"begin":380,"end":382},"obj":"8101399"},{"id":"31489176-10918419-30448261","span":{"begin":425,"end":427},"obj":"10918419"},{"id":"31489176-8101399-30448262","span":{"begin":462,"end":464},"obj":"8101399"},{"id":"31489176-28301051-30448263","span":{"begin":512,"end":514},"obj":"28301051"},{"id":"31489176-11346704-30448264","span":{"begin":565,"end":567},"obj":"11346704"},{"id":"31489176-18422859-30448265","span":{"begin":569,"end":571},"obj":"18422859"},{"id":"31489176-28301051-30448266","span":{"begin":573,"end":575},"obj":"28301051"},{"id":"31489176-18422859-30448267","span":{"begin":600,"end":602},"obj":"18422859"},{"id":"31489176-28301051-30448268","span":{"begin":608,"end":610},"obj":"28301051"},{"id":"31489176-11346704-30448269","span":{"begin":638,"end":640},"obj":"11346704"},{"id":"31489176-18422859-30448270","span":{"begin":642,"end":644},"obj":"18422859"},{"id":"31489176-18422859-30448271","span":{"begin":667,"end":669},"obj":"18422859"},{"id":"31489176-11346704-30448272","span":{"begin":675,"end":677},"obj":"11346704"},{"id":"31489176-28301051-30448273","span":{"begin":707,"end":709},"obj":"28301051"}],"text":"Table 4. Cardiovascular and respiratory adverse reactions observed per number of treatments.\nAdverse reaction Studies Total number of treatments Adverse reactions observed, n (%) (min%–max%) †\nCardiac\n Hypotension ‡ [ 40, 51, 68] 323 10 (3) (2–14) [ 68] - [ 40]\n Hypertension ‡ [ 25, 51, 68] 425 60 (14) (3–21) [ 25] - [ 68]\n Bradycardia (mild and severe) ‡ [ 51] 54 4 (7)\n Decrease in heartrate ‡ [ 39] 32 30 (94)\n Tachycardia ‡ [ 51] 54 4 (7)\n Cardiac event, unspecified ‡ [ 74] 1269 35 (3)\n Chest discomfort/tightness ‡ [ 25, 68, 74] 1640 83 (5) (0–6) [ 68] - [ 74]\nRespiratory\n Dyspnea [ 25, 68] 371 3 (1) (0–2) [ 68] - [ 25]\n Shortness of breath ‡ [ 74] 1269 40 (3)\n†Incidences of the adverse reactions have been calculated for all the individual studies. (%, min-max) are the lowest and highest observed incidence of an adverse reaction observed in the group of studies included.\n‡ DMSO was administered intravenously."}